A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma

Share
Print

Full Title

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Purpose

The purpose of this study is to find the highest dose of the investigational drug IGM-2323 that can be given safely in patients with non-Hodgkin lymphoma (NHL) that has come back or continued to grow despite prior treatment. IGM-2323 is a bispecific antibody that binds to two different proteins at the same time: one on the surface of cancer cells and one on the surface of immune cells called T cells. Researchers believe that IGM-2323 may enhance the ability of a patient’s own T cells to destroy cancer cells. IGM-2323 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have NHL that came back or continued to grow after at least two prior regimens of therapy.
  • Patients may not be candidates for stem cell transplantation.
  • At least 4 weeks must pass since the completion of previous treatment and receipt of IGM-2323.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthew Matasar at 212-639-8889.

Protocol

20-240

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators